GlassScriptPhysician profile
Amy Nau
NPI 1750355467
$5,909.86
in general payments reported to CMS, 2019-2025
20 companies · $962 in 2025
The $962 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $37.21 · 2021: $308 · 2022: $1,745 · 2023: $1,714 · 2024: $833 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $3,230.35 | 2019-2023 | Tearcare System |
| Alcon Vision LLC | $539.74 | 2024-2025 | Precision 7, Clareon, Precision7 |
| Tarsus Pharmaceuticals, INC. | $423.16 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $251.07 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $194.20 | 2023-2025 | Miebo, Xiidra, Infuse |
| Novartis Pharmaceuticals Corporation | $183.55 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $181.74 | 2021-2023 | Acuvue |
| Glaukos Corporation | $140.26 | 2025 | Photrexa Viscous and Photrexa |
| Shire North American Group INC | $123.43 | 2019 | |
| Coopervision INC. | $99.26 | 2019-2023 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $86.06 | 2024-2025 | |
| Rxsight INC | $82.73 | 2024 | Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Abbvie INC. | $81.88 | 2022-2025 | |
| Oyster Point Pharma, INC. | $80.99 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $68.95 | 2023-2024 | Lipiflow System Activator II (Disposable |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $43.04 | 2024-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.02 | 2020-2021 | |
| Optovue, INC. | $28.89 | 2021 | |
| Lombart Brothers, INC. | $21.09 | 2025 | Opd-III |
| Abb Con-Cise Optical Group LLC | $18.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Nau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.